In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
As of close of business last night, Celldex Therapeutics Inc’s stock clocked out at $18.30, up 2.81% from its previous closing price of $17.80. In other words, the price has increased by $2.81 from its previous closing price. On the day, 0.46 million shares were traded. CLDX stock price reached its highest trading level at $18.38 during the session, while it also had its lowest trading level at $17.59.
Ratios:
To gain a deeper understanding of CLDX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 18.91 and its Current Ratio is at 18.91. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Morgan Stanley on March 20, 2025, initiated with a Overweight rating and assigned the stock a target price of $46.
On February 13, 2025, UBS started tracking the stock assigning a Buy rating and target price of $44.
On October 07, 2024, Citigroup started tracking the stock assigning a Buy rating and target price of $70.Citigroup initiated its Buy rating on October 07, 2024, with a $70 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Nov 11 ’24 when Marucci Anthony S bought 11,500 shares for $26.82 per share. The transaction valued at 308,430 led to the insider holds 40,284 shares of the business.
Martin Samuel Bates sold 17,172 shares of CLDX for $608,315 on Jun 14 ’24. The SVP AND CFO now owns 28,125 shares after completing the transaction at $35.42 per share. On Jun 14 ’24, another insider, Crowley Elizabeth, who serves as the SR. VP & CPDO of the company, sold 30,000 shares for $34.87 each. As a result, the insider received 1,045,962 and left with 9,074 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CLDX now has a Market Capitalization of 1214823552 and an Enterprise Value of 493355744. For the stock, the TTM Price-to-Sale (P/S) ratio is 173.05 while its Price-to-Book (P/B) ratio in mrq is 1.63. Its current Enterprise Value per Revenue stands at 70.279 whereas that against EBITDA is -2.571.
Stock Price History:
The Beta on a monthly basis for CLDX is 1.41, which has changed by -0.5181675 over the last 52 weeks, in comparison to a change of 0.0635103 over the same period for the S&P500. Over the past 52 weeks, CLDX has reached a high of $47.00, while it has fallen to a 52-week low of $14.40. The 50-Day Moving Average of the stock is -7.90%, while the 200-Day Moving Average is calculated to be -35.77%.
Shares Statistics:
It appears that CLDX traded 821.21K shares on average per day over the past three months and 993340 shares per day over the past ten days. A total of 66.37M shares are outstanding, with a floating share count of 64.70M. Insiders hold about 2.54% of the company’s shares, while institutions hold 114.74% stake in the company. Shares short for CLDX as of 1743379200 were 8303305 with a Short Ratio of 10.11, compared to 1740700800 on 8875878. Therefore, it implies a Short% of Shares Outstanding of 8303305 and a Short% of Float of 14.469999999999999.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
